Glenmark Pharmaceuticals is planning to set up a new manufacturing facility in the US. The company is planning to set up this manufacturing facility at Monroe Corporate Center, North Carolina USA. The facility will be spread over 100,000 sq. feet (around 15 acre plot) and the company will first begin work on an oral solid unit and thereafter set up manufacturing units for injectables and topical.
The company expects to start manufacturing activity by the end of the current financial year. This facility is dedicated only for the US market and is Glenmark’s first manufacturing facility in North America adding to its list of 14 plants in 4 countries- India, Brazil, Argentina and Czech Republic.
Glenmark which operates in North America through its subsidiary Glenmark Generics Inc. has a fast growing generics business with a robust portfolio of over 90 products authorized for distribution in the U.S. in niche segments like Dermatology, Hormones, Controlled Substances, Oncology and Modified Release products.
